Skip to content
Advertisement

Valeant Pharmaceuticals

Latest Stories

earns_valeant_68607.jpg

earns_valeant_68607.jpg

FILE - This May 27, 2013, file photo, shows the head office and logo of Valeant Pharmaceuticals in Laval, Quebec, Canada. Valeant is selling its CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion. Shares of the pharmaceutical company soared more than 13 percent in Tuesday, Jan. 10, 2017, premarket trading.(Ryan Remiorz/The Canadian Press via AP, File)

valeant_ceo.jpeg

valeant_ceo.jpeg

In this Tuesday, May 19, 2015, file photo, Valeant Pharmaceuticals CEO J. Michael Pearson poses at the company's annual general meeting in Montreal. (Ryan Remiorz/The Canadian Press via AP, File)

3cdbf7cb9921f412530f6a706700a591.jpg

3cdbf7cb9921f412530f6a706700a591.jpg

FILE - This Feb. 6, 2012, file photo, shows William Ackman, of Pershing Square Capital Management, in Toronto. It was announced Monday, May 12, 2014, that Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited bid worth nearly $46 billion undervalues the company and carries significant risk. Shortly after Canada’s Valeant and activist investor Ackman made their offer public last month, Allergan announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive. (AP Photo/The Canadian Press, Pawel Dwulit, File)

None